2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2008-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2008.03.078PMID 18420409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.

  2007cited by this paper
• Non-peptidic urotensin-II receptor modulators

  2006cited by this paper
• The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

  2006cited by this paper
• Novel potent and efficacious nonpeptidic urotensin II receptor agonists.

  2006cited by this paper
• Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.

  2005cited by this paper
• Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

  2005cited by this paper
• Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

  2004cited by this paper
• Plasma concentration of urotensin II is raised in hypertension

  2004cited by this paper
• Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

  2004cited by this paper
• Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

  2004cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects

  2003cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

  2002cited by this paper
• Plasma Urotensin in Human Systolic Heart Failure

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1-Oxides with Trimethylsilanecarbonitrile

  1985cited by this paper

• Synthesis, structural characterization, and thermal properties of octahedral diperchlorato complexes of copper(II) with the chelating 2-aminomethylpiperidine and 2-aminomethylpyridine ligands

  2022cites this paper
• Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice

  2022cites this paper
• Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures

  2013cites this paper
• Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists.

  2012cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Optimization of isochromanone based urotensin II receptor agonists.

  2010cites this paper
• Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

  2009cites this paper
• A regio- and diastereoselective intramolecular nitrone cycloaddition for practical 3- and 2,3-disubstituted piperidine synthesis from gamma-butyrolactone.

  2009cites this paper
• Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2008.

  2009cites this paper
• Chapter 5.1 Five-membered ring systems: thiophenes and Se/Te analogues

  2009cites this paper
• N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.

  2008cites this paper
• Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

  2008cites this paper
• Development of potent and selective small-molecule human Urotensin-II antagonists.

  2008cites this paper
• Aminomethylpiperazines as selective urotensin antagonists.

  2008cites this paper
• Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

  2008cites this paper